Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 19, 2026, 1:49 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 193–216 of 575 matching trials from the live ClinicalTrials.gov search.
Conditions
NASH - Nonalcoholic Steatohepatitis
Interventions
Vertical Sleeve Gastrectomy, Lifestyle Modification Counseling
Procedure · Behavioral
Lead sponsor
University of Minnesota
Other
Eligibility
30 Years to 70 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
4
States / cities
San Francisco, California • Baton Rouge, Louisiana • Minneapolis, Minnesota
Completed Phase 1 Interventional

Pancreatic Clamp in NAFLD

NCT05724134
Conditions
Insulin Resistance, Prediabetic State, Hyperinsulinemia, Non-Alcoholic Fatty Liver Disease, Obesity
Interventions
Insulin human, Octreotide Acetate, Glucagon, Growth Hormone, Human, [6,6-2H2] D-glucose, 20% D-glucose (aq), BOOST Plus, CORE Bar, Harvard Apparatus PHD ULTRA CP syringe pump, Yellow Springs Instruments (YSI) 2500 Biochemistry Glucose/Lactate Analyzer
Drug · Other · Dietary Supplement + 1 more
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 65 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
New York, New York
Enrolling by invitation Not applicable Interventional Accepts healthy volunteers

Biometabolic Outcomes After Weight Loss Surgery: An Individualized Approach

NCT04841057
Conditions
Obesity, Morbid, Metabolic Syndrome, NASH - Nonalcoholic Steatohepatitis
Interventions
50 cm BP limb length, 100 cm BP limb length, 150 cm BP limb length
Procedure
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
18 Years to 80 Years
Enrollment
750 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2031
U.S. locations
1
States / cities
Columbia, Missouri
Conditions
Non-alcoholic Steatohepatitis, Non-alcoholic Fatty Liver Disease
Interventions
Placebo, PF-06865571
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
6
States / cities
Anaheim, California • New Haven, Connecticut • South Miami, Florida + 3 more
Conditions
MASLD/MASH (Metabolic Dysfunction-Associated Steatotic Liver Disease / Metabolic Dysfunction-Associated Steatohepatitis)
Interventions
TVB-2640 25 mg (US), TVB-2640 50 mg (US), Placebo (US), TVB-2640 50 mg (China), Placebo (China), TVB-2640 75 mg (US)
Drug
Lead sponsor
Sagimet Biosciences Inc.
Industry
Eligibility
18 Years and older
Enrollment
142 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
12
States / cities
Chula Vista, California • Montclair, California • Sacramento, California + 9 more
Conditions
NASH - Nonalcoholic Steatohepatitis
Interventions
TERN-201, Placebo
Drug · Other
Lead sponsor
Terns, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years to 75 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
11
States / cities
Tucson, Arizona • Coronado, California • Los Angeles, California + 5 more
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Safety and Tolerability Study of SHP626 in Overweight and Obese Adults

NCT02287779
Conditions
Non-Alcoholic Steatohepatitis
Interventions
SHP626, Placebo
Drug
Lead sponsor
Mirum Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
84 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Knoxville, Tennessee
Conditions
Non-alcoholic Fatty Liver Disease (NAFLD)
Interventions
Metformin, Lifestyle modifications, Fibroscan device (Echosens)
Drug · Behavioral · Device
Lead sponsor
Northwell Health
Other
Eligibility
18 Years to 80 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
Manhasset, New York
Conditions
Familial Partial Lipodystrophy, Nonalcoholic Steatohepatitis, NAFLD
Interventions
Metreleptin
Drug
Lead sponsor
University of Michigan
Other
Eligibility
5 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Ann Arbor, Michigan
Conditions
Non-alcoholic Steatohepatitis
Interventions
Noom Healthy Weight
Behavioral
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Marietta, Pennsylvania
Conditions
Liver Fibrosis Due to NASH
Interventions
Placebo, SIM
Biological
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 65 Years
Enrollment
222 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
41
States / cities
Phoenix, Arizona • Coronado, California • San Diego, California + 34 more
Conditions
Metabolic Dysfunction Associated Steatohepatitis
Interventions
Survodutide, Placebo matching survodutide
Combination Product
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
1,590 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
127
States / cities
Chandler, Arizona • Peoria, Arizona • Scottsdale, Arizona + 99 more
Conditions
Fatty Liver
Interventions
Weight Management (diet, exercise, and behavior modification)
Behavioral
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Providence, Rhode Island
Conditions
Hepatic Encephalopathy, Cirrhosis, Nonalcoholic Steatohepatitis, Hepatitis C
Interventions
Not listed
Lead sponsor
OSF Healthcare System
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
Peoria, Illinois
Conditions
Non-alcoholic Fatty Liver Disease
Interventions
Not listed
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
1
States / cities
San Diego, California
Conditions
Nonalcoholic Fatty Liver
Interventions
Vitamind D
Dietary Supplement
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
48 participants
Timeline
2012 – 2017
U.S. locations
1
States / cities
Cleveland, Ohio
Conditions
Non-alcoholic Steatohepatitis
Interventions
MGL-3196, Placebo
Drug
Lead sponsor
Madrigal Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
26
States / cities
Dothan, Alabama • Tucson, Arizona • Coronado, California + 23 more
Conditions
Nonalcoholic Fatty Liver Disease
Interventions
Endoscopic Sleeve Gastroplasty
Procedure
Lead sponsor
West Virginia University
Other
Eligibility
18 Years to 75 Years
Enrollment
30 participants
Timeline
2022 – 2026
U.S. locations
1
States / cities
Morgantown, West Virginia
Conditions
Non-alcoholic Steatohepatitis
Interventions
Semaglutide, Placebo (semaglutide)
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 75 Years
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
24
States / cities
Chandler, Arizona • Peoria, Arizona • Coronado, California + 21 more
Conditions
Non-alcoholic Fatty Liver Disease
Interventions
PF-06835919, Placebo
Drug · Other
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
New Haven, Connecticut
Conditions
Moderate Liver Impairment, Severe Liver Impairment
Interventions
BMS-986036
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
21 Years to 75 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
3
States / cities
Miami, Florida • Orlando, Florida • San Antonio, Texas
Completed No phase listed Observational Accepts healthy volunteers

Study to Investigate the Pathophysiology of Type 2 Diabetes in Youth

NCT00536250
Conditions
Impaired Glucose Tolerance, Pre-diabetes, Childhood Obesity, Insulin Resistance, Metabolic Syndrome
Interventions
Not listed
Lead sponsor
Yale University
Other
Eligibility
8 Years to 22 Years
Enrollment
255 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2001 – 2017
U.S. locations
1
States / cities
New Haven, Connecticut
Terminated Not applicable Interventional Accepts healthy volunteers

The Role of Microbiome Reprogramming on Liver Fat Accumulation

NCT03914495
Conditions
NAFLD
Interventions
Inulin, Placebo
Dietary Supplement
Lead sponsor
AdventHealth Translational Research Institute
Other
Eligibility
35 Years to 65 Years
Enrollment
57 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Orlando, Florida
Conditions
Psoriatic Arthritis
Interventions
Guselkumab
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
Not listed
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
San Diego, California